Novartis– tag –
-
Novartis’ DM1 Therapeutic Delpacibart Etedesiran Fails to Meet Primary Endpoint in Phase III HARBOR Study
Novartis Switzerland Overview Novartis announced that its antibody-oligonucleotide conjugate (AOC) delpacibart etedesiran (del-desiran) for myotonic dystrophy type 1 (DM1) did not achieve a statistically significant improvement in the pr... -
Isomorphic Labs and Recursion Pharmaceuticals Forge Major AI Drug Discovery Alliances with Pharma Giants
flcube.com International Overview Isomorphic Labs, an Alphabet subsidiary, has secured significant AI-driven drug discovery partnerships with Eli Lilly and Novartis to identify novel small molecule therapeutics for undisclosed targets. C... -
Biotech Alliances Surge: Alteogen-Novartis Subcutaneous Drug Delivery Deal and NewBiologix-Synastra Gene Therapy Manufacturing Partnership Highlight Industry Trends
PharmExec Unknown Overview Alteogen has signed an option and license agreement with Novartis for subcutaneous drug development, while NewBiologix and Synastra announced a partnership to develop stable production cell lines for Duchenne m... -
Novartis Halts Autoimmune CAR-T Trials After Three Patient Deaths, Sparking Safety Debate
Endpoints News USA Overview Novartis has disclosed the deaths of three patients from immune effector cell-associated hemophagocytic lymphohistiocytosis (IEC-HS) complications in clinical trials of its CAR-T cell therapy, rapcabtagene aut... -
Novartis Halts CAR T-Cell Trials Following Patient Deaths in Experimental Therapy
pharmaphorum USA Overview Novartis has temporarily halted eight clinical trials for its experimental CAR T-cell therapy, rapcabtagene autoleucel (rap-cel), following the deaths of three patients from immune effector cell-associated hemop... -
Monte Rosa’s AI-Powered Molecular Glue Degrader MRT-6160 Achieves >90% VAV1 Degradation and Potent Cytokine Suppression in Phase 1, Prompting Multiple Novartis-Led Phase 2 Trials
Quartr Sweden Overview Monte Rosa Therapeutics has announced that its AI-driven QuEEN platform's molecular glue degrader (MGD) MRT-6160 achieved over 90% VAV1 protein degradation and potent cytokine suppression in Phase 1 trials. This su... -
Gilead Report Highlights RNA Therapeutic Progress: GSK/Ionis HBV ASO Shows Positive Phase 3, Novartis FSHD siRNA Promising Early Data
The Bio Report USA Overview A Gilead report underscores significant advancements in RNA therapeutic clinical trials, with GSK/Ionis's beoprovirsen, an ASO targeting HBV, demonstrating positive Phase 3 results. Novartis's siRNA therapy, D... -
Generate Biomedicines’ AI-Designed Antibody GB-0895 Advances to Global Phase 3 for Severe Asthma; Insilico Medicine’s IPF Drug also Reaches Phase 3
Stock Titan USA Overview Generate Biomedicines announced its AI-designed anti-TSLP monoclonal antibody, GB-0895, has advanced to global Phase 3 clinical trials for severe asthma, highlighted in its Q2 2026 financial results. Novartis has... -
Isomorphic Labs: AI-Designed Drugs Head to Human Trials, Reshaping Pharma’s Future
Wired USA Overview Isomorphic Labs, a Google DeepMind spin-off, is on the verge of commencing human clinical trials for drugs entirely designed by artificial intelligence. Leveraging its foundational AlphaFold system, the company aims to... -
Novartis’ CAR-T Cell Therapy Tisagenlecleucel Shows Durable Efficacy in Pediatric and Young Adult ALL
CancerNetwork USA Overview Novartis' CAR-T cell therapy, tisagenlecleucel (Kymriah), continues to demonstrate durable efficacy and safety in pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia ...
12